Results 241 to 250 of about 186,598 (292)

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring

Arthritis &Rheumatology, EarlyView.
Objective Using a hydroxychloroquine (HCQ) dose of 5 mg/kg/day in systemic lupus erythematosus (SLE) is associated with a higher risk of flares; HCQ blood level monitoring could be a better way to adjust the HCQ dose. We studied the upper threshold for a reference range of HCQ levels to inform routine monitoring.
Shivani Garg, Benoît Blanchet, Yann Nguyen, Fauzia Hollnagel, Ada Clarke, Michelle Petri, Murray B. Urowitz, John G. Hanly, Caroline Gordon, Sang‐Cheol Bae, Juanita Romero‐Diaz, Jorge Sanchez‐Guerrero, Ann E. Clarke, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey‐Goldman, Susan Manzi, Andreas Jönsen, Graciela S. Alarcón, Ronald F. Van Vollenhoven, Cynthia Aranow, Véronique Le Guern, Meggan Mackay, Guillermo Ruiz‐Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Søren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Jill Buyon, Julie Chezel, Alicja Puszkiel, Nathalie Costedoat‐Chalumeau   +42 more
wiley   +1 more source

Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab

Arthritis &Rheumatology, EarlyView.
Objective The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post hoc analysis of the RITAZAREM clinical trial.
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators, Reem Al‐jayyousi, Yoshihiro Arimura, Jacqueline Andrews, Simon Bond, Marianna Nodale, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Michael Clarkson, Janak de Zoysa, Vimal Derebail, Tim Doulton, Tomomi Endo, Eri Muso, Tatsuo Tsukamoto, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz‐Singer, Yoshitomo Hamano, Lorraine Harper, Toshiko Ito‐Ihara, Rachel B. Jones, Nader Khalidi, Rainer Klocke, Curry L. Koening, Yoshinori Komagata, Hajime Kono, Shunya Uchida, Carol A. Langford, Peter Lanyon, Sarah Lawman, Raashid Luqmani, Larry W. Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Ken‐ei Sada, Richard Smith, Richard Watts, Robert Spiera, Antoine G. Sreih, Kazuo Suzuki, Vladamir Tesar, Augusto Vaglio, Giles Walters, Caroline Wroe   +62 more
wiley   +1 more source

Moving the Needle on Health System Care Delivery: From Observation to Intervention. [PDF]

Ann Surg
Harbaugh C, Broman K.
europepmc   +1 more source

Visual Hypersensitivity as a Transdiagnostic Marker of Surgical Pain Response in Arthritis and Chronic Pain Syndromes

Arthritis &Rheumatology, EarlyView.
Objective Nociplastic pain is pain primarily driven by the central nervous system and, unlike nociceptive pain conditions, is thought to be refractory to peripherally directed therapies. Nociplastic pain is also associated with hypersensitivity to painful and other sensory stimuli (such as visual stimuli). Nonpainful sensory measures have not been well
Noah Waller, Steven E. Harte, Richard E. Harris, Andrew Schrepf, Tristin Smith, Eric Ichesco, Chelsea Kaplan, Flavia Sunzini, Deeba Minhas, Wendy Marder, Sara R. Till, David A. Williams, Chad M. Brummett, Neil Basu, Sawsan As‐Sanie, Daniel J. Clauw   +15 more
wiley   +1 more source

Measuring the Impact: Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth With Axial Disease

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes (PROs) in youth with axial juvenile spondyloarthritis (axJSpA) initiating tumor necrosis factor inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source

A Roadmap to Excellence: Insights From Quality Structures of Top-Performing Healthcare Organizations. [PDF]

Am J Med Qual
Cerese J, Chang P, Graves K, Grubeling N, Ikezuagu M, Levine D, Lu A, Miller M, Schaal S, Sauls T, Siddiqui M.   +10 more
europepmc   +1 more source

Digital economy development and global value chain network centralization. [PDF]

PLoS One
Yuan H, Yue M, Wang R, Ren B, Li X.
europepmc   +1 more source

The future of trauma care in Germany 2030: challenges, opportunities, and strategic directions. [PDF]

Eur J Trauma Emerg Surg
Spering C, Lemm M, Finke S, Wrobel M, Haering A, Franke A, Sprengel K, Seemann R, Bieler D.   +8 more
europepmc   +1 more source

The 'social gradient' in primary liver cancer in France: A national observational study. [PDF]

JHEP Rep
Strigalev M, Fuks D, Katsahian S, Parlati L, Marchese U, Conticchio M, Ronde-Roupie C, Nassar A, Dhote A, Mallet V, Tzedakis S.   +10 more
europepmc   +1 more source

(De)centralized Water Futures: Key Dimensions of Infrastructure, Governance, and Operations. [PDF]

WIREs Water
Cooperman AD, Rempel JL, Adams EA, Cantor A, Fuerte MM, Osborne-Gowey J, Wilson NJ, Workman CL, Beresford M, Harris LM, Méndez-Barrientos LE, Shah SH, Wutich A, Stoler J.   +13 more
europepmc   +1 more source